Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2003
05/01/2003WO2003035079A1 A combination product comprising melagatran and dexamethasone
05/01/2003WO2003035078A1 Combined use of catalytic antioxidants and glutathion or lipoic acid
05/01/2003WO2003035077A1 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
05/01/2003WO2003035076A1 Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
05/01/2003WO2003035075A1 Inhibitors of human phosphatidyl-inositol 3-kinase delta
05/01/2003WO2003035074A1 Drugs comprising combination of triazaspiro[5,5]undecane derivative with cytochrome p450 isozyme 3a4 inhibitor and/or p-glycoprotein inhibitor
05/01/2003WO2003035073A1 Isoxazoline derivatives useful as antimicrobials
05/01/2003WO2003035072A1 Use of flibanserin in the treatment of sexual disorders
05/01/2003WO2003035070A1 Antihistaminic/antitussive compositions
05/01/2003WO2003035069A1 Apomorphine-containing dosage form for ameliorating male erectile dysfunction
05/01/2003WO2003035068A1 Macrolides containing pharmaceutical compositions
05/01/2003WO2003035067A1 Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents
05/01/2003WO2003035065A1 Benzimidazoles and analogues and their use as protein kinases inhibitors
05/01/2003WO2003035064A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
05/01/2003WO2003035062A1 Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
05/01/2003WO2003035061A1 Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake
05/01/2003WO2003035060A1 Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
05/01/2003WO2003035059A2 Spermicides
05/01/2003WO2003035058A2 Polymaleide compounds and their medical use
05/01/2003WO2003035057A1 Inhibitors of dipeptidyl peptidase iv
05/01/2003WO2003035056A1 Combination of liponic acid and glutamine in food and pharmaceutical products
05/01/2003WO2003035055A1 Mch antagonists for the treatment of obesity
05/01/2003WO2003035054A1 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
05/01/2003WO2003035053A1 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
05/01/2003WO2003035052A1 Preventives/remedies for viral infection
05/01/2003WO2003035051A2 The use of proton sequestering agents in drug formulations
05/01/2003WO2003035050A2 Use of tyrosine kinase inhibitors for promoting hair growth
05/01/2003WO2003035049A2 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
05/01/2003WO2003035048A2 Methods for the treatment of osteoarthritis and compositions thereof
05/01/2003WO2003035047A2 Combinations comprising a selective cyclooxygenase-2 inhibitor
05/01/2003WO2003035046A2 Salts formed of an at1-receptor antagonist and a cardiovascular agent
05/01/2003WO2003035043A2 Pharmaceutical formulation comprising more than 15% tamoxifen
05/01/2003WO2003035042A1 Use of a multi-layer controlled-release tablet comprising ropinirole for the manufacture of medicament for the treatment of fibromyalgia
05/01/2003WO2003035041A1 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
05/01/2003WO2003035040A1 Methods of treatment using a gastric retained gabapentin dosage
05/01/2003WO2003035039A1 Methods of treatment using a gastric retained losartan dosage
05/01/2003WO2003035037A1 Solid pharmaceutical formulation for a piperazine urea derivative
05/01/2003WO2003035036A1 Montelukast granule formulation
05/01/2003WO2003035035A1 Novel process
05/01/2003WO2003035031A1 Stable composition comprising particles in a frozen aqueous matrix
05/01/2003WO2003035030A1 Kit for the preparation of a pharmaceutical composition
05/01/2003WO2003035029A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
05/01/2003WO2003035028A1 Modulating charge density to produce improvements in the characteristics of spray-dried proteins
05/01/2003WO2003035027A1 Chewable tablet containing lysine
05/01/2003WO2003035012A2 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
05/01/2003WO2003035009A2 Treatment of acute myeloid leukemia with indolinone compounds
05/01/2003WO2003035008A2 Functionalized stilbene derivatives as improved vascular targeting agents
05/01/2003WO2003035007A2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
05/01/2003WO2003035005A2 Heteroindanes: a new class of potent cannabimimetic ligands
05/01/2003WO2003035004A2 Immunotherapy for reversing immune suppression
05/01/2003WO2003035002A2 Management of postoperative pain
05/01/2003WO2003035000A2 Method for treating non-neuropathic pain
05/01/2003WO2003034999A2 Medication and method for remediating existing scars through transdermal topical delivery of calcium channel blockers
05/01/2003WO2003034998A2 Composition and method for treating erectile dysfunction and reducing fibrosis in erectile tissue of the human penis
05/01/2003WO2003034994A2 Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
05/01/2003WO2003034992A2 Diindolylmethane for the treatment of hpv infection
05/01/2003WO2003034991A2 Taste masking spill-resistant formulation
05/01/2003WO2003034988A2 Injectable compositions for the controlled delivery of pharmacologically active compound
05/01/2003WO2003034987A2 Androgen receptor modulators and methods of use thereof
05/01/2003WO2003034981A2 Prevention of recurrent viral disease
05/01/2003WO2003034980A2 A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same
05/01/2003WO2003034978A2 Antidiabetic 2-substituted-5'-o- (1-boranotriphosphate) adenosine derivatives
05/01/2003WO2003034961A1 Terazosin transdermal device and methods
05/01/2003WO2003034903A2 Psma antibodies and protein multimers
05/01/2003WO2003034900A2 Sterile, breathable patch for treating wound pain
05/01/2003WO2003034825A1 Anthelmintic composition
05/01/2003WO2003026680A3 Method and topical formulation for treating skin conditions associated with aging
05/01/2003WO2003026637A3 Dosage form for treatment of diabetes mellitus
05/01/2003WO2003026628A3 Composite dosage forms having an inlaid portion
05/01/2003WO2003020283A3 Method for treating diabetic retinopathy
05/01/2003WO2003018018A3 Vinorelbine compositions and methods of use
05/01/2003WO2003017976B1 Synergistic mixed poloxamer systems for the solubilisation of drugs
05/01/2003WO2003014063A3 Protected 3.5-dihydroxy-2.2-dimethyl-valeroamides for the synthesis of epothilone and derivatives and method for the production and use thereof
05/01/2003WO2003013656A3 Non-peptide ccr1 receptor antagonists for the treatment of progressive renal fibrosis
05/01/2003WO2003008412A3 Hetero-bicyclic crf antagonists
05/01/2003WO2003007955A3 Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
05/01/2003WO2003007912A3 Lyophilized formulation comprising olanzapine
05/01/2003WO2003005989A3 Granulates containing liposoluble substances and a process for the preparation thereof
05/01/2003WO2003005970A3 Carvedilol polymorph
05/01/2003WO2003004008A3 Pharmaceutical composition for prophylaxis and treatment of calcium metabolism disorders comprising clodronate in combination with glyceryl palmitostearate
05/01/2003WO2003003981A3 Compositions for improving mental performance
05/01/2003WO2003002109A8 Use of tyrosine kinase inhibitors for treating autoimmune diseases
05/01/2003WO2003000777A3 Multi-arm block copolymers as drug delivery vehicles
05/01/2003WO2003000242A3 Method for the treatment of lymphedema using guaifenesin
05/01/2003WO2003000010A3 Adenosyl-cobalamin fortified compositions
05/01/2003WO2002102782A3 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE
05/01/2003WO2002102297A3 Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
05/01/2003WO2002100828A3 Process for the production of zaleplon
05/01/2003WO2002100351A3 A method for treating inflammatory diseases by administering a ppar-delta agonist
05/01/2003WO2002100336A3 Tissue-specific endothelial membrane proteins
05/01/2003WO2002100295A3 Facially amphiphilic polymers as anti-infective agents
05/01/2003WO2002099055A3 Cips as modifiers of the p53 pathway and method of use
05/01/2003WO2002099046A3 Spo11 as modifier of the p53 pathway and methods of use
05/01/2003WO2002098843A3 Certain salts of discodermolide acid, pharmaceutical compositions containing them and their use in treating tumors
05/01/2003WO2002098347A3 Methods and compositions that affect melanogenesis (pfi-016cip/pct)
05/01/2003WO2002096435A3 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
05/01/2003WO2002094840A3 Tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing same
05/01/2003WO2002094247A3 Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
05/01/2003WO2002094215A3 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
05/01/2003WO2002092072A3 Drugs for the treatment of the alzheimer disease
1 ... 5483 5484 5485 5486 5487 5488 5489 5490 5491 5492 5493 5494 5495 5496 5497 5498 5499 5500 5501 5502 5503 ... 7860